

Djibouti

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.35 (0.23–0.49)	39 (26–56)
Mortality (HIV+TB only)	0.035 (<0.01–0.11)	4 (0.26–13)
Incidence (includes HIV+TB)	3.4 (2.6–4.2)	378 (291–476)
Incidence (HIV+TB only)	0.2 (0.15–0.25)	22 (17–28)
Incidence (MDR/RR-TB)**	0.18 (0.089–0.27)	20 (10–30)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.17 (0.08–0.27)	1.1 (0.58–1.5)	1.2 (0.66–1.8)
Males	0.2 (0.12–0.27)	1.9 (1.4–2.4)	2.1 (1.6–2.7)
Total	0.37 (0.25–0.49)	3 (2.5–3.5)	3.4 (2.6–4.2)

TB case notifications, 2015	
Total cases notified	2 692
Total new and relapse	2 686
- % tested with rapid diagnostics at time of diagnosis	51%
- % with known HIV status	90%
- % pulmonary	57%
- % bacteriologically confirmed among pulmonary	78%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.12 (0.07–0.18)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	142	6%
- on antiretroviral therapy	138	97%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			100 (65–140)
Estimated % of TB cases with MDR/RR-TB	4.3% (1.8–6.8)	34% (21–46)	
% notified tested for rifampicin resistance	5%	930%	1 349
MDR/RR-TB cases tested for resistance to second-line drugs		10	
Laboratory-confirmed cases		MDR/RR-TB: 85, XDR-TB: 7	
Patients started on treatment ****		MDR/RR-TB: 71, XDR-TB: 1	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	81%	1 240
Previously treated cases, excluding relapse, registered in 2014		
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically